155 related articles for article (PubMed ID: 30593980)
21. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
[TBL] [Abstract][Full Text] [Related]
22. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Kappos L; Hartung HP; Freedman MS; Boyko A; Radü EW; Mikol DD; Lamarine M; Hyvert Y; Freudensprung U; Plitz T; van Beek J;
Lancet Neurol; 2014 Apr; 13(4):353-63. PubMed ID: 24613349
[TBL] [Abstract][Full Text] [Related]
23. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
[TBL] [Abstract][Full Text] [Related]
24. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
25. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
[TBL] [Abstract][Full Text] [Related]
26. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
[TBL] [Abstract][Full Text] [Related]
27. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
[TBL] [Abstract][Full Text] [Related]
28. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Smits RC; Emmen HH; Bertelsmann FW; Kulig BM; van Loenen AC; Polman CH
Neurology; 1994 Sep; 44(9):1701-5. PubMed ID: 7936300
[TBL] [Abstract][Full Text] [Related]
29. 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis.
Polman CH; Bertelsmann FW; de Waal R; van Diemen HA; Uitdehaag BM; van Loenen AC; Koetsier JC
Arch Neurol; 1994 Nov; 51(11):1136-9. PubMed ID: 7980110
[TBL] [Abstract][Full Text] [Related]
30. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of group cognitive rehabilitation therapy in multiple sclerosis.
Mani A; Chohedri E; Ravanfar P; Mowla A; Nikseresht A
Acta Neurol Scand; 2018 Jun; 137(6):589-597. PubMed ID: 29411360
[TBL] [Abstract][Full Text] [Related]
32. A Randomized Trial to Assess the Efficacy and Safety of ABT-126, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, in the Treatment of Cognitive Impairment in Schizophrenia.
Haig GM; Bain EE; Robieson WZ; Baker JD; Othman AA
Am J Psychiatry; 2016 Aug; 173(8):827-35. PubMed ID: 26940805
[TBL] [Abstract][Full Text] [Related]
33. Study protocol for a randomised, double-blind, placebo-controlled 12-week pilot phase II trial of Sailuotong (SLT) for cognitive function in older adults with mild cognitive impairment.
Steiner GZ; Bensoussan A; Liu J; Hohenberg MI; Chang DH
Trials; 2018 Sep; 19(1):522. PubMed ID: 30253809
[TBL] [Abstract][Full Text] [Related]
34. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the effect of adding Fish oil to Fingolimod on TNF-α, IL1β, IL6, and IFN-γ in patients with relapsing-remitting multiple sclerosis: A double-blind randomized placebo-controlled trial.
Zandi-Esfahan S; Fazeli M; Shaygannejad V; Hasheminia J; Badihian S; Aghayerashti M; Maghzi H
Clin Neurol Neurosurg; 2017 Dec; 163():173-178. PubMed ID: 29126030
[TBL] [Abstract][Full Text] [Related]
36. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
Miller DH; Weber T; Grove R; Wardell C; Horrigan J; Graff O; Atkinson G; Dua P; Yousry T; Macmanus D; Montalban X
Lancet Neurol; 2012 Feb; 11(2):131-9. PubMed ID: 22226929
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of a Computer-Assisted Cognitive Rehabilitation Intervention in Relapsing-Remitting Multiple Sclerosis Patients: A Multicenter Randomized Controlled Trial.
Messinis L; Nasios G; Kosmidis MH; Zampakis P; Malefaki S; Ntoskou K; Nousia A; Bakirtzis C; Grigoriadis N; Gourzis P; Papathanasopoulos P
Behav Neurol; 2017; 2017():5919841. PubMed ID: 29463950
[TBL] [Abstract][Full Text] [Related]
38. Cognitive correlates of under-ambiguity and under-risk decision making in high-functioning patients with relapsing remitting multiple sclerosis.
Cogo MG; Rota S; Fusco ML; Mapelli C; Ferri F; Appollonio IM; Isella V
J Clin Exp Neuropsychol; 2014; 36(10):1066-75. PubMed ID: 25486588
[TBL] [Abstract][Full Text] [Related]
39. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.
Kappos L; Li D; Calabresi PA; O'Connor P; Bar-Or A; Barkhof F; Yin M; Leppert D; Glanzman R; Tinbergen J; Hauser SL
Lancet; 2011 Nov; 378(9805):1779-87. PubMed ID: 22047971
[TBL] [Abstract][Full Text] [Related]
40. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study.
Hanagasi HA; Gurvit H; Unsalan P; Horozoglu H; Tuncer N; Feyzioglu A; Gunal DI; Yener GG; Cakmur R; Sahin HA; Emre M
Mov Disord; 2011 Aug; 26(10):1851-8. PubMed ID: 21500280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
